BMS-794833 Clinical Trials

Size	Price	Qty
5mg	USD 170
50mg	USD 970

Clinical Trials

A clinical trial sponsored by Bristol-Myers Squibb evaluated the prodrug form of BMS-794833 as an ascending multiple-dose study in subjects with advanced or metastatic solid tumors. This Phase 1 investigation was withdrawn prior to active completion. Consequently, available clinical records for this agent remain limited to an industry-sponsored Phase 1 trial.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00792558	Withdrawn	Advanced Solid Tumors	Bristol-Myers Squibb	2009-01	Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the BMS-794833 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

BMS-794833 acts as a potent ATP-competitive inhibitor of receptor tyrosine kinases, specifically c-Met and vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking autophosphorylation and downstream oncogenic signal transduction to arrest tumor cell proliferation. By suppressing growth factor-driven oncogenic signaling and vascular development, the compound prevents tumor expansion, providing a mechanistic rationale for targeting advanced solid tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).